XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition and Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue Recognition and Collaborative Arrangements        
Total net revenue from GSK $ 61,680 $ 48,643 $ 181,146 $ 147,697
Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
Total net revenue from GSK 61,680 48,422 181,146 147,034
Revenue from collaborative arrangements from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue from GSK 0 221 0 663
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue from GSK 61,680 48,643 181,146 147,697
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 65,136 51,878 191,514 157,402
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
Total net revenue from GSK 61,680 48,422 181,146 147,034
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 51,745 44,604 155,420 137,938
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 9,769 7,274 29,149 19,464
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 3,622 0 6,945 0
Strategic alliance - MABA program license | GSK | Revenue from collaborative arrangements from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue from GSK $ 0 $ 221 $ 0 $ 663